STOCKS TELEGRAPH

Tag: NYXH Stock Price

  • Nyxoah (NYXH) Stock Experiences Significant After-Market Gains

    Nyxoah (NYXH) Stock Experiences Significant After-Market Gains

    Following the announcement that Nyxoah S.A. (NASDAQ: NYXH) will be attending many upcoming investor events, the company’s shares experienced a sharp rise. After-hours trading saw NYXH stock rise 6.68% to $7.99, more than offsetting a -2.73% loss it had sustained during regular session trading, which concluded at $7.49.

    NYXH To Take Part in Important Investor Conferences

    It has been revealed that Nyxoah (NYXH) will present at three significant investor conferences that will take place in New York City. The CEO of Nyxoah, Olivier Taelman, will provide an update on the business next Monday at the Baird Global Healthcare Conference.

    Following that, the CEO of the firm will also take part to provide such updates to more investors on Tuesday at the HC Wainwright 26th Annual Global Investment Conference and on September 18, 2024 at the Cantor Global Healthcare Conference. In addition, Nyxoah will arrange one-on-one meetings with attending institutional investors.

    Nyxoah Celebrated The Strategic Advancements and Milestones

    In recognition of its significant achievements, Nyxoah was given the privilege to ring the Nasdaq Closing Bell on August 29, 2024. The introduction of the company’s Genio hypoglossal nerve stimulation technology to the US market was also a cause for celebration. Obstructive sleep apnea (OSA) is a major breathing problem that happens during sleep and is associated with cardiovascular illnesses and an increased risk of mortality.

    Financial Position and Market Readiness

    The U.S. healthcare market represents a crucial opportunity for Nyxoah, given its size and strategic importance. Nyxoah is well-positioned for a successful market debut because to solid clinical findings from the DREAM trial, significant finance, and a strengthened U.S. marketing team.

    The FDA has received the last module of Nyxoah’s Premarket clearance (PMA) filing, and U.S. clearance is expected by the end of 2024. The Genio system may be made available in the United States as early as 2025, assuming clearance is given.

    Nyxoah has also announced positive results from the DREAM study and is building its U.S. commercial team, led by Scott Holstine as Chief Commercial Officer. The company’s market entry is fully financed following the successful raising of over €85 million, which includes €48.5 million from an equity offering and a €37.5 million loan agreement with the European Investment Bank (EIB).

  • Why Is Nyxoah (NYXH) Stock On An Upswing Today?

    Why Is Nyxoah (NYXH) Stock On An Upswing Today?

    Nyxoah S.A. (NASDAQ: NYXH) witnessed a remarkable surge of 25.00% in its stock during the current session, reaching $7.00. Despite the absence of noteworthy news directly influencing this spike, attention turns to recent developments that may be fueling positive investor sentiment.

    In preparation for forthcoming investor meetings, Nyxoah (NYXH) disclosed its strategic priorities for 2024 last week. Notably, the company successfully concluded patient follow-up in the DREAM U.S. pivotal study and is set to release efficacy and safety data by early April. At the SLEEP 2023 event, 12-month efficacy data for the initial 34 DREAM patients and safety data for all DREAM patients were presented.

    The results showcased a 65% AHI responder rate, a 76% ODI responder rate, and safety metrics in line with expectations. NYXH also submitted the fourth and final module in the modular PMA submission and plans to submit the final module shortly after announcing DREAM results.

    In anticipation of a late 2024 launch, the company heightened investments in its U.S. commercial organization, appointing Francis Kim as Chief Regulatory and Quality Officer and expanding market access to secure reimbursement upon launch. Furthermore, Nyxoah successfully completed enrollment in the ACCCESS complete concentric collapse (CCC) U.S. pivotal study.

    Recently unveiled investigator-sponsored data in Europe highlighted Genio’s efficacy in treating CCC patients. Genio’s unique single-incision, leadless, upgradable design, controlled by a wearable, resonated positively with both clinicians and patients, resulting in a robust European launch.

    Genio’s bilateral stimulation allows for the treatment of CCC, and the label was expanded to encompass patients who, having failed CPAP, previously had major palate surgery as their only treatment option. Nyxoah is poised on the brink of a historic milestone with the imminent release of DREAM results in the coming months.

    The company anticipates completing the PMA submission shortly thereafter and is expediting manufacturing and commercial investments to replicate its European success in the U.S. This marks a pivotal moment in Nyxoah’s trajectory, underlining its commitment to innovation and growth.